ArticleScientific reports2017
Circulating Biomarkers to Identify Responders in Cardiac Cell therapy.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Gene Therapy for Heart Failure.Journal of cardiovascular translational research · 2026Review
- Integrin β2 Plays a Significant Role in Therapeutic Angiogenesis Through Hematopoietic Stem Cell Transplantation.Life (Basel, Switzerland) · 2025Article
- [Diagnostics (Basel, Switzerland) · 2023Article
- Recommendations for nomenclature and definition of cell products intended for human cardiovascular use.Cardiovascular research · 2022Article
- Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study.American heart journal plus : cardiology research and practice · 2022Review
- Non-Coding RNAs in Stem Cell Regulation and Cardiac Regeneration: Current Problems and Future Perspectives.International journal of molecular sciences · 2021Review
- Screening for regenerative therapy responders in heart failure.Biomarkers in medicine · 2021Review
- Flavin Binding Allosteric Aptamer with Noncovalent Labeling for miR Sensing.Bioconjugate chemistry · 2019Article
- Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review.Stem cells translational medicine · 2019Review
- Artificial Intelligence for Cardiac Imaging-Genetics Research.Frontiers in cardiovascular medicine · 2019Review
- Engineering molecular imaging strategies for regenerative medicine.Bioengineering & translational medicine · 2018Review
- Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology.Cardiovascular research · 2018Review
- Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions.Circulation research · 2018Review
- Recent Progress in Stem Cell Modification for Cardiac Regeneration.Stem cells international · 2018Review
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 10 institutions in 2 countries.
Funding
Abstract
Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.